Skip to main content

Table 3 Factors associated with overweight

From: HIV infection, and overweight and hypertension: a cross-sectional study of HIV-infected adults in Western Kenya

 

N

n

%

OR

95% CI

P value

aOR

95% CI

P value

Age category

 18–29

33

4

12.1

1.00

   

1.00

   

 30–39

104

20

19.2

1.72

0.54

5.47

0.353

1.99

0.61

6.46

0.251

 40 and older

114

18

15.8

1.35

0.42

4.33

0.604

1.43

0.44

4.66

0.545

Sex

 Male

82

9

11.0

1.00

   

1.00

   

 Female

169

33

19.5

1.96

0.89

4.33

0.093

2.11

0.94

4.72

0.070

Marital status

 Single

7

2

28.6

1.00

   

1.00

   

 Married

154

25

16.2

0.48

0.08

2.63

0.402

0.53

0.09

3.05

0.478

 Divorced

10

1

10.0

0.27

0.01

3.88

0.341

0.38

0.02

5.69

0.484

 Widowed

80

14

17.5

0.53

0.09

3.02

0.474

0.58

0.09

3.51

0.558

Education level

 Low education

96

14

14.6

1.00

   

1.00

   

 Complete primary

117

22

18.8

1.35

0.65

2.82

0.414

1.59

0.74

3.44

0.229

 Complete secondary or higher

38

6

15.8

1.09

0.38

3.11

0.859

1.59

0.50

5.04

0.429

Occupation

 At home

31

5

16.1

1.00

   

1.00

   

 Working outside

48

10

20.8

1.36

0.41

4.47

0.603

1.36

0.40

4.59

0.620

 Working inside

136

20

14.7

0.89

0.31

2.61

0.841

0.83

0.27

2.47

0.738

 Others

36

7

19.4

1.26

0.35

4.44

0.724

1.29

0.34

4.82

0.695

SES

 Poorest

63

13

20.6

1.00

   

1.00

   

 Poor

62

9

14.5

0.65

0.25

1.66

0.371

0.67

0.26

1.74

0.419

 Less poor

62

13

21.0

1.02

0.43

2.42

0.963

0.95

0.39

2.31

0.926

 Rich

63

7

11.1

0.48

0.17

1.30

0.1491

0.42

0.15

1.16

0.096

Physical activity level

 Inactive

11

2

18.2

1.00

   

1.00

   

 Minimally active

22

4

18.2

1.00

0.15

6.53

1

0.92

0.13

6.29

0.933

 HEPA active

215

36

16.7

0.91

0.18

4.36

0.9011

0.80

0.15

4.04

0.791

Chai per day

 0–1 cup

20

3

15.0

1.00

   

1.00

   

 2 cups

58

11

19.0

1.32

0.32

5.33

0.691

1.19

0.28

4.94

0.803

 3 cups or more

173

28

16.2

1.09

0.30

3.98

0.8913

0.96

0.25

3.63

0.963

Soda per week

 None

126

23

18.3

1.00

   

1.00

   

 Once

64

7

10.9

0.55

0.22

1.36

0.196

0.49

0.19

1.25

0.141

 Twice or more

61

12

19.7

1.10

0.50

2.38

0.8157

0.99

0.44

2.21

0.984

Ugali per day

 Quarter a plate

185

32

17.3

1.00

   

1.00

   

 Half a plate

55

8

14.5

0.81

0.35

1.88

0.631

0.97

0.40

2.31

0.946

 3 quarters a plate or more

8

1

12.5

0.68

0.08

5.74

0.7257

0.74

0.08

6.60

0.789

Alcohol

 No

223

35

15.7

1.00

   

1.00

   

 Yes

24

5

20.8

1.41

0.49

4.03

0.5179

1.66

0.54

5.04

0.367

Smoke

 No

242

41

16.9

1.00

   

1.00

   

 Yes

9

1

11.1

0.61

0.07

5.03

0.648

0.91

0.10

8.20

0.935

Abdominal obesity

 No

138

21

15.2

1.00

   

1.00

   

 Yes

113

21

18.6

1.27

0.65

2.46

0.477

0.94

0.43

2.03

0.885

Hypertension

 No

222

35

15.8

1.00

   

1.00

   

 Yes

28

7

25.0

1.78

0.70

4.51

0.223

2.04

0.77

5.39

0.147

ART duration

 0–364 days

14

4

28.6

1.00

   

1.00

   

 365 days and more

237

38

16.0

0.48

0.14

1.60

0.231

0.52

0.15

1.84

0.314

CD4 counts (cells/μl)

 < 200

30

3

10.0

1.00

   

1.00

   

 200–499

113

20

17.7

1.93

0.53

7.01

0.315

2.08

0.55

7.79

0.276

 ≥ 500

106

19

17.9

1.96

0.54

7.15

0.3053

1.94

0.51

7.31

0.326

On PI

 No

214

39

18.2

1.00

   

1.00

   

 Yes

36

2

5.6

0.41

0.11

1.39

0.1537

0.45

0.12

1.57

0.323

PI duration

 0–359 days

7

1

14.3

1.00

   

1.00

   

 540 days and more

28

2

7.1

0.46

0.03

5.96

0.553

   

0.999

WHO stage

 1

51

8

15.7

1.00

   

1.00

   

 2

71

17

23.9

1.69

0.66

4.29

0.268

1.85

0.71

4.86

0.208

 3

97

12

12.4

0.75

0.28

1.99

0.576

0.74

0.27

2.02

0.563

 4

29

5

17.2

1.11

0.32

3.81

0.8562

1.04

0.28

3.79

0.946

OI history

 No

204

30

14.7

1.00

   

1.00

   

 Yes

45

12

26.7

2.11

0.98

4.53

0.0562

2.46

1.10

5.50

0.028

  1. N number of study participants, n number of elements in a sample, OR odds ratio, 95% CI 95% confidential interval, aOR adjusted odds ratio, P value probability value, HEPA health-enhancing physical activity, ART anti-retroviral therapy, PI protease inhibitor, WHO stage WHO clinical staging of HIV/AIDS for adults and adolescent, OI opportunistic infection